OCTIMET Oncology NV

📍 Beerse, Belgium👥 4 employees💰 Last funded Feb 2017
Research Services🌐 octimet.com
Website LinkedIn
OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen. Headed by Dr. Timothy Perera (CEO), OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Netherlands
1
Belgium
1
Frequently asked questions
Who invested in OCTIMET Oncology NV?
OCTIMET Oncology NV has 2 investors on record on gritt.io.
When did OCTIMET Oncology NV last raise funding?
The most recent investment in OCTIMET Oncology NV recorded on gritt.io was in February 2017.
What industry is OCTIMET Oncology NV in?
OCTIMET Oncology NV operates in Research Services. Find similar Research Services investors on gritt.io.
Where is OCTIMET Oncology NV based?
OCTIMET Oncology NV is headquartered in Beerse, Belgium.